Introduction
============

Leukemia is one of the 10 leading causes of cancer-associated mortality in China; in 2011 there were 27,907 mortalities in men and 19,708 mortalities in women from leukemia ([@b1-ol-0-0-6686]). The four types of Leukemia are acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia (AML) and chronic myeloid leukemia. AML accounts for \~80% of cases of acute leukemia in adults ([@b2-ol-0-0-6686]).

AML is a highly heterogeneous leukemia associated with excessive progenitor cell proliferation and a differentiation block for cell-cycle arrest. AML is often caused by karyotypic abnormalities, including chromosomal translocations, deletions and inversions ([@b3-ol-0-0-6686],[@b4-ol-0-0-6686]). Etiological factors driving AML development remain unclear, but lifestyle and environmental exposures, including obesity and smoking, are reported to be associated with the disease ([@b5-ol-0-0-6686]).

The French-American-British (FAB) and World Health Organization (WHO) systems are the two main AML classification systems. The FAB system classifies AML into subtypes M0-M7 according to the cell type from which AML develops and the degree of maturation of the cells ([@b6-ol-0-0-6686]). According to the 2008 WHO Classification, AML are classified into six subgroups: AML with recurring genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, not otherwise specified AML, myeloid proliferations related to down syndrome and blastic plasmacytic dendritic cell neoplasms, with diagnosis performed according to morphology, cytochemistry, immunophenotype, genetics and clinical features ([@b7-ol-0-0-6686]).

Karyotypic abnormalities and genetic mutations are associated with AML progression and prognosis. Translocation of chromosomes 15 and 17 \[t(15;17)\], t(8;21) or inversion of chromosome 16 is predictive of a relatively good prognosis ([@b8-ol-0-0-6686]), whereas deletion of chromosome 7, deletion of 5q or \>3 chromosomal abnormalities is predictive of a poor prognosis in AML patients ([@b9-ol-0-0-6686],[@b10-ol-0-0-6686]). Fms-like tyrosine kinase 3-internal duplication (*FLT3*-ITD) and nucleophosmin (*NPM1*) are the two most commonly mutated genes in AML patients. Mutations to *NPM1* occur in 50% of AML patients, whereas mutations to *FLT3*-ITD occur in 30%. *FLT3*-ITD, KIT proto-oncogene receptor tyrosine kinase and brain and acute leukemia, cytoplasmic gene mutations have a negative impact on AML prognosis ([@b11-ol-0-0-6686],[@b12-ol-0-0-6686]), while *NPM1* and CCAAT/enhancer binding protein-α have a positive impact on prognosis ([@b12-ol-0-0-6686]--[@b14-ol-0-0-6686]).

At present, the pathogenic mechanism of AML is unclear. Acute promyelocytic leukemia (APL) is an M3 subtype of AML according to the FAB classification system. Overexpression of microRNA (miRNA/miR)-125a decreases APL NB4 cell proliferation, the inhibition of cell cycle progression and the promotion of cell apoptosis by targeting the ErbB pathway in APL ([@b15-ol-0-0-6686]). miR-150 expression induces the myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. In AML patient samples and cell lines, miR-150 expression is low or absent, which contributes to the blocking of myeloid differentiation in acute leukemia cells ([@b16-ol-0-0-6686]).

The aim of the present study was to identify featured target genes of significantly differentially expressed miRNAs in AML by comparing AML samples with healthy ones, and analyzing the correlation of miRNA-target genes. Candidate target genes identified by these approaches may provide the groundwork for the elucidation of the mechanism of AML. However, further investigation of the potential function of these genes in the treatment of AML is required.

Materials and methods
=====================

### Transcriptomics datasets

In the Gene Expression Omnibus (GEO; <http://ncbi.nlm.nih.gov/geo/>) ([@b17-ol-0-0-6686]), only the studies comparing AML and healthy blood were assessed. A total of 6 studies were assessed in which the global profile of gene expression was measured in AML patients\' blood samples, with accession numbers GSE48558, GSE35008, GSE35010, GSE24395, GSE17054 and GSE51908. The details of studies, including the platform, number of cases, controls, year and author, were extracted and assessed.

### Data processing and identification of differentially expressed miRNAs and mRNAs

Raw expression datasets were downloaded from the GEO and the raw datasets were preprocessed by log~2~ transformation and Z-score normalization. Limma, which is a linear model for microarray data analysis, was utilized to analyze the differentially expressed miRNAs and mRNAs between the AML and healthy control samples ([@b18-ol-0-0-6686]). A false discovery rate (FDR) of \<0.05 was set as the threshold of differentially expressed miRNAs and mRNAs.

### miRNA target gene prediction

Targets genes for differentially expressed miRNAs were predicted via miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>). Over 50,000 miRNA-target interactions in the miRTarBase database have been validated by experiments such as reporter assays, western blotting or microarray experiments with overexpression or knockdown of miRNAs ([@b19-ol-0-0-6686],[@b20-ol-0-0-6686]).

### Construction of regulatory miRNA-mRNA networks

The miRNA-mRNA interaction network of differentially expressed miRNA and mRNA was visualized using Cytoscape (<http://cytoscape.org>) ([@b21-ol-0-0-6686]). This software presents the regulation between miRNA and mRNA as two-dimensional network with nodes and edges, which represent miRNA-target gene associations.

### Functional enrichment analysis of the differentially expressed target genes

To obtain the functions of differentially expressed targeted genes, Gene Ontology (GO) terms ([@b22-ol-0-0-6686]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b23-ol-0-0-6686]) pathways were enriched using GOEAST (<http://omicslab.genetics.ac.cn/GOEAST>) ([@b24-ol-0-0-6686]) and GeneCodis (<http://genecodis.cnb.csic.es/analysis>), respectively ([@b25-ol-0-0-6686]). P\<0.01 and FDR \<0.05 were set as the thresholds of significance for GO terms and KEGG pathway analysis.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The blood samples were collected from 3 males with AML treated in Qilu Hospital of Shandong University (Shandong, China) in 2015, with a mean age of 45.6 years. In addition, 3 normal blood samples were also included with corresponding gender and age. Total RNA of fresh blood samples were extracted by TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. Use of these samples was approved by the Ethics Committee of Qilu Hospital of Shandong University (Jinan, China). The SuperScript III Reverse Transcription kit (Invitrogen; Thermo Fisher Scientific, Inc.) was used to synthesize the cDNA according to the manufacturer\'s instructions. RT-qPCR was performed using Power SYBR Green PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on the Applied Biosystems 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The RT-qPCR cycling conditions were 1 cycle of 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec and 60°C for 60 sec. The miRcute miRNA First-Strand cDNA kit (Tiangen Biotech Co., Ltd., Bejing, China) and the miRcute miRNA qPCR Detection kit (Tiangen Biotech Co., Ltd.) were used for miRNA expression level detection. The RT-qPCR cycling conditions for miRNA were 1 cycle of 94°C for 2 min, followed by 45 cycles of 94°C for 20 sec and 60°C for 34 sec. U6 small nuclear RNA and β-actin was used as internal controls for miRNA and mRNA detection, respectively. The relative expression of target genes was calculated using the 2^−ΔΔCq^ method ([@b26-ol-0-0-6686]). At least three independent experiments were performed. The PCR primers used were as follows: hsa-miR-155 forward, 5′-TAATGCTAATCGTGATAGGGGT-3′ and reverse, GTGCAGGGTCCGAGGT; hsa-miR-192 forward, 5′-TGACCTATGAATTGACAGCC-3′ and reverse, GTGCAGGGTCCGAGGT; frizzled class receptor 3 (*FZD3*) forward, 5′-TCTCCTCTTAGCTGGCATTATATCC-3′ and reverse, 5′-GCAGCGTTCTTGTATCCACGTT-3′; and Annexin A2 (*ANXA2*) forward, 5′-AGAATCATGGTCTCCCGCAGTG-3′ and reverse, 5′-TCCACCACACAGGTACAGCAGC-3′.

### Statistical analysis

RT-qPCR experimental data was expressed as the mean ± standard deviation. Statistical significance was evaluated using an unpaired Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Differentially expressed miRNAs and mRNAs in AML

A total of 5 mRNA and 1 miRNA expression profiles datasets, including 137 AML and 84 healthy samples were downloaded from the GEO, normalized and processed ([Table I](#tI-ol-0-0-6686){ref-type="table"}) ([@b27-ol-0-0-6686]--[@b31-ol-0-0-6686]). Differentially expressed genes between AML and normal samples, including 86 miRNAs and 468 mRNAs, were screened with a threshold of FDR\<0.05. Of the 86 miRNAs, 47 were upregulated and 39 were downregulated in AML samples compared with the normal samples; of the 468 mRNAs, 401 were upregulated and genes 67 were downregulated. The top 10 upregulated and downregulated miRNAs are shown in [Table II](#tII-ol-0-0-6686){ref-type="table"} (the full list of differentially expressed miRNAs and mRNAs is not shown).

### Construction of miRNA-mRNA regulatory networks

The miRTarBase database was used to predict the target genes of the 47 upregulated and 39 downregulated miRNAs in AML; 223 miRNA-target gene pairs, including 31 differentially expressed miRNAs and 153 target genes, were visualized using Cytoscape software ([Fig. 1](#f1-ol-0-0-6686){ref-type="fig"}). A total of 55 differentially expressed miRNAs, including hsa-miR-29b-1\* and hsa-miR-194, were not displayed in the network, as the 55 differentially expressed miRNAs were not available in miRTarBase database (data not shown). hsa-miR-26b, hsa-miR-192, hsa-miR-21, hsa-miR-181a and hsa-miR-155 regulated 43, 25, 26, 15 and 11 targets, respectively, and displayed the highest connectivity. Pleomorphic adenoma gene 1 (*PLAG1*), high-mobility group AT-hook 2, RUN-domain-containing 3B, transmembrane protein 2, TNF-α induced protein 3 and family with sequence similarity 3 member C, which were regulated by 7, 5, 4, 4, 4 and 4 miRNAs, respectively, were the mRNAs with the highest connectivity ([Fig. 1](#f1-ol-0-0-6686){ref-type="fig"}).

### Functional analysis of miRNA target genes

GO classification and KEGG pathway analyses were used to obtain the biological functions of miRNA target genes, including biological process, cellular component, molecular function and signaling pathway. The threshold of GO classification was set as P\<0.01. Negative regulation of blood coagulation (GO:0030195, P=1.83×10^−24^), negative regulation of hemostasis (GO:1900047, P=1.83×10^−24^) and negative regulation of coagulation (GO:0050819, P=2.65×10^−23^) were the most significantly enriched target genes of biological processes; sarcolemma (GO:0042383, P=1.85×10^−29^), Schmidt-Lanterman incisure (GO:0043220, P=1.80×10^−25^) and myelin sheath adaxonal region (GO:0035749, P=5.91×10^−25^) were the most significantly enriched target genes of the cellular component; and phospholipase inhibitor activity (GO:0004859, P=1.14×10^−44^), lipase inhibitor activity (GO:0055102, P=3.76×10^−43^) and calcium-dependent phospholipid binding (GO:0005544, P=5.77×10^−41^) were the most significantly enriched target genes of the molecular function ([Table III](#tIII-ol-0-0-6686){ref-type="table"}).

In total, 148 of the 153 differentially expressed miRNA target genes were enriched in the KEGG database. The Wnt signaling pathway (FDR=8.70×10^−4^), melanogenesis (FDR=8.70×10^−4^) and pathways in cancer (FDR=1.60×10^−3^) were the most significantly enriched pathways in KEGG analysis, with the criteria of FDR\<0.05 ([Table IV](#tIV-ol-0-0-6686){ref-type="table"}).

### RT-qPCR validation of differentially expressed miRNAs and target genes

To validate the microarray analysis data, the levels of significant differentially expressed miRNA and target genes were quantified by RT-qPCR in three AML blood samples and three normal blood samples. hsa-miR-155 was significantly (P\<0.05) upregulated in AML compared with that in the normal samples, and the target gene *ANXA2* was significantly downregulated in AML ([Fig. 2A](#f2-ol-0-0-6686){ref-type="fig"}). *FZD3* was significantly upregulated in the three AML samples compared with the normal samples (P\<0.01; [Fig. 2B](#f2-ol-0-0-6686){ref-type="fig"}). The present study identified hsa-miR-192 as a downregulated miRNA in AML, although the expression level was not found to be significantly different in AML by RT-qPCR validation ([Fig. 2C](#f2-ol-0-0-6686){ref-type="fig"}).

Discussion
==========

In the present study, hsa-miR-155 was one of the five miRNAs with the highest connectivity with target genes, targeting 11 differentially expressed mRNAs ([Fig. 1](#f1-ol-0-0-6686){ref-type="fig"}), and was significantly upregulated in AML. In the present study, *ANXA2* was predicted as a putative target gene of hsa-miR-155. RT-qPCR validated that hsa-miR-155 was significantly upregulated and *ANXA2* was significantly downregulated in AML ([Fig. 2A](#f2-ol-0-0-6686){ref-type="fig"}), which is in accordance with the bioinformatics analysis. The fact that hsa-miR-155 was upregulated in AML was consistent with the results of a previous study ([@b32-ol-0-0-6686]). Mounting evidence identifies hsa-miR-155 as having an oncogenic role, generating AML; overexpression of hsa-miR-155 causes myeloproliferation with cell cell-cycle arrest ([@b33-ol-0-0-6686],[@b34-ol-0-0-6686]). High expression of hsa-miR-155 is associated with a poor outcome in AML patients, which has been observed in numerous AML patients via sequencing studies and miRNA expression analyses ([@b35-ol-0-0-6686]--[@b37-ol-0-0-6686]). Additionally, hsa-miR-155 is reported to contribute to the metastasis of various solid tumors, including colorectal carcinoma ([@b38-ol-0-0-6686]), oral squamous cell carcinoma ([@b39-ol-0-0-6686]) and renal cell carcinoma ([@b40-ol-0-0-6686]). *ANXA2* is a target gene of hsa-miR-155 and its downregulation is associated with a poor AML patient prognosis, based on gene expression profile analysis ([@b41-ol-0-0-6686]). hsa-miR-155 upregulation and *ANXA2* downregulation may be potential biomarkers for the clinical evaluation of AML prognosis.

Through KEGG analysis, *FZD3* was found to be enriched in four signaling pathways, including the Wnt signaling pathway, melanogenesis, pathways in cancer and basal cell carcinoma. The Wnt signaling pathway was the most significantly enriched pathway in AML ([Table IV](#tIV-ol-0-0-6686){ref-type="table"}). Higher expression of *FZD3* was detected in three AML patients compared with that in the normal control, as determined by RT-qPCR ([Fig. 2B](#f2-ol-0-0-6686){ref-type="fig"}), which was consistent with the bioinformatics analysis. *FZD3* is a member of the frizzled gene family, which also includes *FZD1* and *FZD7*, and functions as a receptor for the canonical Wnt/β-catenin signaling pathway. Overactivation of the Wnt signaling pathway contributes to tumorigenesis ([@b42-ol-0-0-6686],[@b43-ol-0-0-6686]). According to the present study, the Wnt signaling pathway was essential for AML progression and oncogenicity. CXXC finger protein 5, which is frequently deleted in AML, inhibits the Wnt pathway and leukemic cell proliferation ([@b44-ol-0-0-6686]). Activation of the Wnt/β-catenin pathway mediates transformation of AML progenitor cells and results in impaired myelomonocytic differentiation ([@b45-ol-0-0-6686],[@b46-ol-0-0-6686]). The FZD3/Wnt signaling pathway may therefore be important in AML pathogenesis.

In the present study, hsa-miR-192 was the most significantly downregulated miRNA and regulated 25 target genes in AML ([Fig. 1](#f1-ol-0-0-6686){ref-type="fig"}). miR-192 downregulation is associated with cell cycle progression, cell growth, apoptosis and proliferation of solid tumors ([@b47-ol-0-0-6686],[@b48-ol-0-0-6686]). Overexpression of miR-192 induces apoptotic death in bladder cancer cells, increases the proportion of cells in the G0/G1 phase and decreases the proportion of cells in the S phase compared with a control ([@b47-ol-0-0-6686]). Curcumin is a traditional Chinese medicine extracted from turmeric that inhibits non-small cell lung cancer cell (NSCLC) cell proliferation and induces NSCLC cell apoptosis through the upregulation of miR-192-5p and the suppression of the phosphoinositide-3 kinase/protein kinase B signaling pathway ([@b47-ol-0-0-6686],[@b48-ol-0-0-6686]). In the present study, hsa-miR-192 was downregulated in AML ([Fig. 2C](#f2-ol-0-0-6686){ref-type="fig"}), suggesting that it may also serve a key role in AML cell apoptosis and proliferation.

*PLAG1* was targeted by 7 miRNAs, meaning it had the highest connectivity of the mRNAs in the miRNA-mRNA network ([Fig. 1](#f1-ol-0-0-6686){ref-type="fig"}). The PLAG family consists of 3 members (PLAG1, PLAGL1 and PLAGL2), each with a highly conserved zinc finger structure that allows them to function as transcription factors to recognize DNA and/or RNA ([@b49-ol-0-0-6686]). PLAG1 serves an oncogenic role in AML, cooperating with CBF-SMMHC to induce AML tumorigenesis ([@b50-ol-0-0-6686]). The results of the present study revealed that PLAG1 was upregulated in AML.

In summary, a miRNA-mRNA regulatory network was constructed based on differentially expressed miRNAs and target genes in AML. In this network, a number of miRNAs and target genes that may play important roles in AML, such as hsa-miR-155, hsa-miR192, ANXA2, FZD3 and PLAG1, were identified. These results indicated that the Wnt signaling pathway, melanogenesis and pathways in cancer may be involved in the pathogenesis of AML. An miRNA-target gene regulatory network was constructed in AML using bioinformatic tools. A number of miRNAs and mRNAs that are potentially important for AML tumorigenesis were identified. However, the mechanism behind the associations between miRNA, mRNA and miRNA-mRNA involved in AML progression and development requires further investigation.
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![miRNA-target gene regulatory network of acute myeloid leukemia. Circular nodes represent target genes and diamond nodes represent miRNAs. Green nodes represent downregulation, red nodes represent upregulation. Solid lines indicate regulatory associations between the miRNAs and target genes. miRNA/miR, microRNA.](ol-14-04-3981-g00){#f1-ol-0-0-6686}

![Verification of miRNA and target gene expression levels in AML and normal controls, as determined by reverse transcription-quantitative polymerase chain reaction. (A) hsa-miR-155 and *ANXA2* expression levels in AML patients and healthy controls. (B) *FZD3* expression levels in AML patients and healthy controls. (C) hsa-miR-192 expression levels in AML patients and healthy controls. \*P\<0.05, \*\*P\<0.01. miRNA/miR, microRNA; AML, acute myeloid leukemia; *ANXA2*, annexin A2; *FZD3*, frizzled class receptor 3; CON, healthy control patient blood samples; LEU, AML patient blood samples.](ol-14-04-3981-g01){#f2-ol-0-0-6686}

###### 

Characteristics of mRNA and miRNA expression profiling of the acute myeloid leukemia.

  A, mRNA expression profiling                                                                                                                                             
  ------------------------------- ---------------------------- -------------------------------------------------------------------------------------------- -------------- ----------------------
  Civin *et al*, 2013             GSE48558                     GPL6244 \[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]   49:18          ([@b27-ol-0-0-6686])
  Barreyro *et al*, 2012          GSE35008                     GPL6244 \[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array                                 16:12          ([@b28-ol-0-0-6686])
  Barreyro *et al*, 2012          GSE35010                     GPL6244 \[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array                                 16:15          ([@b28-ol-0-0-6686])
  Kikushige *et al*, 2010         GSE24395                     GPL6106 Sentrix Human-6 v2 Expression BeadChip                                               5:12           ([@b29-ol-0-0-6686])
  Majeti R *et al*, 2009          GSE17054                     GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        4:9            ([@b30-ol-0-0-6686])
                                                                                                                                                                           
  B, miRNA expression profiling                                                                                                                                            
                                                                                                                                                                           
  Author, year                    Gene expression omnibus ID   Platform                                                                                     Samples, H:P   (Refs.)
                                                                                                                                                                           
  Tan YS *et al*, 2013            GSE51908                     GPL8786 \[miRNA-1_0\] Affymetrix miRNA Array                                                 47:18          ([@b31-ol-0-0-6686])

H, healthy subject; P, AML patient; miRNA, microRNA.

###### 

Significantly differentially expressed miRNAs (top 10).

  miRNA                  P-value        Log (fold-change)
  ---------------------- -------------- -------------------
  Upregulated miRNAs                    
    hsa-miR-432          9.93×10^−12^     1.66
    hsa-miR-126          7.44×10^−10^     1.57
    hsa-miR-10a          4.35×10^−8^      1.55
    hsa-miR-130a         3.39×10^−11^     1.54
    hsa-miR-34a          2.05×10^−14^     1.43
    hsa-miR-181d         2.32×10^−13^   1.3
    hsa-miR-181a\*       6.65×10^−10^   1.3
    hsa-miR-551b\*       3.27×10^−8^      1.17
    hsa-miR-501-5p       1.17×10^−8^      1.08
    hsa-miR-125b         6.04×10^−5^      1.06
  Downregulated miRNAs                  
    hsa-miR-192          6.74×10^−7^      −1.12
    hsa-miR-29b-1\*      2.75×10^−8^    −1.1
    hsa-miR-194          1.66×10^−5^    −1.1
    hsa-miR-31           2.98×10^−3^      −1.05
    hsa-miR-26b          6.59×10^−8^        −0.971
    hsa-miR-628-3p       6.31×10^−4^        −0.755
    hsa-miR-30e          2.84×10^−4^        −0.715
    hsa-miR-29b          1.53×10^−4^        −0.664
    hsa-miR-200c         3.06×10^−5^        −0.635
    hsa-miR-21           3.96×10^−3^        −0.605

miRNA/miR, microRNA.

###### 

GO annotation of differentially expressed microRNA target genes in acute myeloid leukemia samples (top 15).

  GO ID                GO Term                                                   Count   P-value
  -------------------- --------------------------------------------------------- ------- --------------
  Biological process                                                                     
    GO:0030195         Negative regulation of blood coagulation                  21      1.83×10^−24^
    GO:1900047         Negative regulation of hemostasis                         21      1.83×10^−24^
    GO:0050819         Negative regulation of coagulation                        21      2.65×10^−23^
    GO:0042730         Fibrinolysis                                              17      1.90×10^−22^
    GO:0040023         Establishment of nucleus localization                     16      2.55×10^−22^
    GO:0051961         Negative regulation of nervous system development         14      2.70×10^−22^
    GO:0051964         Negative regulation of synapse assembly                   14      2.70×10^−22^
    GO:0030198         Extracellular matrix organization                         35      6.31×10^−21^
    GO:0043062         Extracellular structure organization                      35      6.58×10^−21^
    GO:0051241         Negative regulation of multicellular organismal process   40      2.08×10^−20^
    GO:0001525         Angiogenesis                                              35      2.86×10^−20^
    GO:0060252         Positive regulation of glial cell proliferation           15      3.64×10^−20^
    GO:0030320         Cellular monovalent inorganic anion homeostasis           14      3.68×10^−20^
    GO:0030644         Cellular chloride ion homeostasis                         14      3.68×10^−20^
    GO:0055064         Chloride ion homeostasis                                  14      3.68×10^−20^
  Cellular component                                                                     
    GO:0042383         Sarcolemma                                                33      1.85×10^−29^
    GO:0043220         Schmidt-Lanterman incisure                                18      1.80×10^−25^
    GO:0035749         Myelin sheath adaxonal region                             17      5.91×10^−25^
    GO:0043218         Compact myelin                                            18      2.95×10^−23^
    GO:0005925         Focal adhesion                                            30      1.69×10^−21^
    GO:0005924         Cell-substrate adherens junction                          30      3.04×10^−21^
    GO:0030055         Cell-substrate junction                                   30      1.30×10^−20^
    GO:0070161         Anchoring junction                                        32      1.09×10^−17^
    GO:0005912         Adherens junction                                         31      1.73×10^−17^
    GO:0043209         Myelin sheath                                             18      2.16×10^−15^
    GO:0019897         Extrinsic to plasma membrane                              18      2.01×10^−13^
    GO:0019898         Extrinsic to membrane                                     18      4.02×10^−10^
    GO:0030054         Cell junction                                             40      1.61×10^−09^
    GO:0014704         Intercalated disc                                         14      2.10×10^−09^
    GO:0044291         Cell-cell contact zone                                    14      3.13×10^−09^
  Molecular function                                                                     
    GO:0004859         Phospholipase inhibitor activity                          29      1.14×10^−44^
    GO:0055102         Lipase inhibitor activity                                 29      3.76×10^−43^
    GO:0005544         Calcium-dependent phospholipid binding                    35      5.77×10^−41^
    GO:0030234         Enzyme regulator activity                                 79      1.58×10^−23^
    GO:0004857         Enzyme inhibitor activity                                 43      1.15×10^−22^
    GO:0005509         Calcium ion binding                                       65      2.23×10^−20^
    GO:0005546         Phosphatidylinositol-4,5-bisphosphate binding             18      2.28×10^−20^
    GO:0005543         Phospholipid binding                                      53      7.37×10^−19^
    GO:1901981         Phosphatidylinositol phosphate binding                    19      2.81×10^−17^
    GO:0008289         Lipid binding                                             56      1.54×10^−15^
    GO:0043548         Phosphatidylinositol 3-kinase binding                     14      6.81×10^−14^
    GO:0008092         Cytoskeletal protein binding                              51      1.35×10^−13^
    GO:0017137         Rab GTPase binding                                        17      1.55×10^−13^
    GO:0004713         Protein tyrosine kinase activity                          25      1.43×10^−12^
    GO:0035091         Phosphatidylinositol binding                              22      2.75×10^−11^

GO, Gene Ontology.

###### 

KEGG pathway enrichment analysis of differentially expressed microRNA target genes in acute myeloid leukemia (top 15).

  KEGG ID    KEGG term                                Count   FDR           Genes
  ---------- ---------------------------------------- ------- ------------- ------------------------------------------------------------------
  hsa04310   Wnt signaling pathway                    4       8.70×10^−4^   *FZD7*, *PLCB4*, *FZD1*, *FZD3*
  hsa04916   Melanogenesis                            4       8.70×10^−4^   *FZD7*, *PLCB4*, *FZD1*, *FZD3*
  hsa05200   Pathways in cancer                       8       1.60×10^−3^   *FZD7*, *AKT3*, *FZD1*, *LAMC1*, *FZD3*, *PTK2*, *ARNT2*, *PLD1*
  hsa05146   Amoebiasis                               4       2.65×10^−3^   *PLCB4*, *LAMC1*, *PTK2*, *COL5A1*
  hsa05222   Small cell lung cancer                   3       2.90×10^−3^   *AKT3*, *LAMC1*, *PTK2*
  hsa04010   MAPK signaling pathway                   6       3.04×10^−3^   *DUSP16*, *RASGRP1*, *RPS6KA6*, *RAPGEF2*, *AKT3*, *CACNB2*
  hsa05217   Basal cell carcinoma                     3       3.59×10^−3^   *FZD7*, *FZD1*, *FZD3*
  hsa04724   Glutamatergic synapse                    4       4.75×10^−3^   *SLC1A6*, *PLCB4*, *TRPC1*, *PLD1*
  hsa04530   Tight junction                           4       5.01×10^−3^   *JAM2*, *MYH10*, *AKT3*, *MPDZ*
  hsa04630   Jak-STAT signaling pathway               4       8.08×10^−3^   *IL15*, *AKT3*, *MPL*, *SPRED1*
  hsa04060   Cytokine-cytokine receptor interaction   5       9.00×10^−3^   *IL15*, *BMPR1B*, *MPL*, *IL1RAP*, *ACVR2A*
  hsa04660   T-cell receptor signaling pathway        3       1.57×10^−2^   *RASGRP1*, *AKT3*, *PDK1*
  hsa04510   Focal adhesion                           4       1.61×10^−2^   *AKT3*, *LAMC1*, *PTK2*, *COL5A1*
  hsa04722   Neurotrophin signaling pathway           3       2.02×10^−2^   *RPS6KA6*, *AKT3*, *PDK1*
  hsa05145   Toxoplasmosis                            3       2.12×10^−2^   *AKT3*, *LAMC1*, *PDK1*

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.

[^1]: Contributed equally
